The FDA drug database lists a supplement dated 25 September 2026 to an abbreviated new drug application for ketoconazole held by a generic manufacturer. The record names only the application and the company; it gives no detail of what changed.
A supplement to a generic application is usually an administrative or manufacturing update and is not a new indication or a safety communication. Without the text of the notice, nothing here changes how ketoconazole should be used. Prescribers should rely on the current product information for the specific brand they supply, and in India on CDSCO-approved labelling, which this record does not address.
- No new safety communication or indication is described in this record
- Check the current labelling for the product you dispense
- Oral ketoconazole has a recognised hepatotoxicity risk, so existing monitoring advice stands
- Indian labelling is set by CDSCO and may differ from US documents
Why it matters
Regulatory database entries are easy to mistake for safety news when they are routine filings.
Don't overread it
A licence supplement is not a new indication, and this entry gives no safety finding.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for infectious diseases, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free